AR028699A1 - Nueva formulacion - Google Patents

Nueva formulacion

Info

Publication number
AR028699A1
AR028699A1 ARP010102759A ARP010102759A AR028699A1 AR 028699 A1 AR028699 A1 AR 028699A1 AR P010102759 A ARP010102759 A AR P010102759A AR P010102759 A ARP010102759 A AR P010102759A AR 028699 A1 AR028699 A1 AR 028699A1
Authority
AR
Argentina
Prior art keywords
refers
treatment
new formulation
formulations
blocker
Prior art date
Application number
ARP010102759A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR028699A1 publication Critical patent/AR028699A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente se refiere a formulaciones farmacéuticas que comprenden un beta-bloqueante, en una dosis de mantenimiento inferior a los 50 mg, particularmente, dentro de un rango entre los 25 a 47 mg, que opcionalmente contienen un agente para reducir el colesterol, mezclado con un adyuvante, diluyente o portador farmacéuticamente aceptable, así como también, se refiere a un método para el tratamiento y el uso de las formulaciones para el tratamiento de la ateroesclerosis y enfermedades relacionadas.
ARP010102759A 2000-06-22 2001-06-11 Nueva formulacion AR028699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002354A SE0002354D0 (sv) 2000-06-22 2000-06-22 New formulation

Publications (1)

Publication Number Publication Date
AR028699A1 true AR028699A1 (es) 2003-05-21

Family

ID=20280209

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102759A AR028699A1 (es) 2000-06-22 2001-06-11 Nueva formulacion

Country Status (28)

Country Link
US (2) US20030191177A1 (es)
EP (1) EP1296716B1 (es)
JP (1) JP2003535875A (es)
KR (1) KR20030010750A (es)
CN (1) CN1437484A (es)
AR (1) AR028699A1 (es)
AT (1) ATE344675T1 (es)
AU (1) AU2001274766A1 (es)
BG (1) BG107373A (es)
BR (1) BR0111790A (es)
CA (1) CA2411100A1 (es)
CZ (1) CZ20024181A3 (es)
DE (1) DE60124400T2 (es)
EE (1) EE200200703A (es)
ES (1) ES2274892T3 (es)
HK (1) HK1054508A1 (es)
HU (1) HUP0302371A3 (es)
IL (1) IL153245A0 (es)
IS (1) IS6653A (es)
MX (1) MXPA02012957A (es)
NO (1) NO20026177D0 (es)
NZ (1) NZ523188A (es)
PL (1) PL360484A1 (es)
RU (1) RU2271802C2 (es)
SE (1) SE0002354D0 (es)
SK (1) SK18072002A3 (es)
WO (1) WO2001097751A2 (es)
ZA (1) ZA200209908B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053683A1 (en) * 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100836321B1 (ko) 2006-10-31 2008-06-09 현대자동차주식회사 차량용 모니터 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175187A (en) * 1989-03-06 1992-12-29 Soorianarain Baligadoo Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
US5455269A (en) * 1989-03-06 1995-10-03 Baligadoo; Soorianarain Synergistic compositions of amiodarone and beta blockers
ES2093833T3 (es) * 1991-03-18 1997-01-01 Sepracor Inc Composicion y metodo que contiene (s)-metoprolol opticamente puro.
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
NO177455C (no) * 1993-06-04 1995-09-20 Gerrit Elmenhorst Anordning ved apparat for fremstilling av brannslukkende skum
EP0904082A4 (en) * 1996-04-17 2001-09-26 Merck & Co Inc COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
SE9602762D0 (sv) * 1996-07-12 1996-07-12 Astra Ab Carton and blank for forming the same
US5998458A (en) * 1997-06-25 1999-12-07 University Technology Corporation Method of treating heart failure
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
KR20020002367A (ko) * 1998-12-23 2002-01-09 윌리암스 로저 에이 심혈관 징후를 위한 조합물

Also Published As

Publication number Publication date
HK1054508A1 (zh) 2003-12-05
ES2274892T3 (es) 2007-06-01
KR20030010750A (ko) 2003-02-05
IS6653A (is) 2002-12-11
ZA200209908B (en) 2004-03-05
BR0111790A (pt) 2003-05-20
US20060252814A1 (en) 2006-11-09
NO20026177L (no) 2002-12-20
DE60124400D1 (de) 2006-12-21
ATE344675T1 (de) 2006-11-15
MXPA02012957A (es) 2003-05-15
DE60124400T2 (de) 2007-10-31
CA2411100A1 (en) 2001-12-27
BG107373A (bg) 2003-09-30
NO20026177D0 (no) 2002-12-20
WO2001097751A2 (en) 2001-12-27
EP1296716A2 (en) 2003-04-02
AU2001274766A1 (en) 2002-01-02
NZ523188A (en) 2006-06-30
EE200200703A (et) 2004-08-16
SE0002354D0 (sv) 2000-06-22
HUP0302371A3 (en) 2007-03-28
HUP0302371A2 (hu) 2003-11-28
CN1437484A (zh) 2003-08-20
SK18072002A3 (sk) 2003-08-05
US20030191177A1 (en) 2003-10-09
JP2003535875A (ja) 2003-12-02
RU2271802C2 (ru) 2006-03-20
CZ20024181A3 (cs) 2003-04-16
EP1296716B1 (en) 2006-11-08
PL360484A1 (en) 2004-09-06
WO2001097751A3 (en) 2002-03-28
IL153245A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
ES2113444T3 (es) Medicamentos.
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
UY28510A1 (es) Compuestos quimicos
UY27870A1 (es) Nuevos derivados de quinuclidina-amida
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
AR012304A1 (es) Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR027360A1 (es) Composicion farmaceutica
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
AR025060A1 (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal